Sanofi May Be Confusing Consumers With Its Rebranding of Famotidine as Zantac 360
Sanofi sold ranitidine for decades without informing customers that it may cause cancer before eventually being caught
Wednesday, May 19, 2021 - Thousands of former Zantac ranitidine are suing Sanofi for negligence and fraud by failing to warn them the medicine could cause cancer. Millions of people trusted their Zantac ranitidine brand and allegedly developed one type of digestive system cancer or another. Zantac ranitidine has been replaced by Zantac 360 famotidine for those seeking to alleviate heartburn and acid reflux pain and discomfort. Zantac 360 famotidine users should be aware of the potential health risks. The new Zantac 360 famotidine is more potent than the original made from ranitidine, and it may be logical to assume that the side effects could be even worse. Visit Zantac antacid cancer lawsuit to learn more.
Sanofi is desperately trying to hang on to the billions of dollars in sales that they once made, ever since the Food and Drug Administration (FDA) banned all forms of ranitidine, of which Zantac was the best-selling, over fears the compound was unstable and naturally degraded once inside the stomach to catastrophically high levels of N-nitrosodimethylamine (NDMA), a deadly carcinogen. Immediately after the ban, the FDA recommended that Zantac users switch to PPI drugs. Doctors are now hesitant to prescribe a replacement medicine for ranitidine since the makers of PPI drugs Prilosec, Nexium, and Pepcid are being sued for allegedly causing kidney damage. Studies also show that people on PPI drugs may be much more likely to have type-2 diabetes. Thousands of Zantac cancer lawsuits could make their way through the court system starting in 2023. Lawsuits accuse Sanofi and GalaxoSmithKline of fraud and negligence for lying to government regulators and consumers about ranitidine being unstable and turning into NDMA.
Famotidine is a more potent and longer-lasting antacid medicine but takes longer to take effect. According to the National Institute of Health, "Famotidine, an H2-receptor antagonist with a thiazolyl nucleus, is approximately 7.5 times more potent than ranitidine." Also, the NIH tells readers that they do not know how the side effects of famotidine will compare to ranitidine. "Additional clinical experience, as well as cost and safety factors, will determine the place of famotidine in treating and preventing acid-peptic disorders," the NIH wrote. The American Council on Science and Health (ACSH) is skeptical of Zantac‘s marketing maneuver and calls it just a form of "bait and switch." The author of a recent article for the online magazine informs readers that Sanofi has tried this type of marketing deception before. Sanofi is telling customers that their Zantac product now contains famotidine but, in reality, it is famotidine that is now being called Zantac. The author tells readers that Sanofi‘s marketing strategy is to make small, insignificant changes to its product and re-label them as breakthrough features like using the term extra strength and longer-lasting. This enables the company to get pharmacy shelf space for three or four times as many products which are 99% similar to one another.
